Cardiovascular Diabetology
-
Publication Venue For
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.. 18:138. 2019
- Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.. 18:116. 2019
- Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.. 17:118. 2018
- Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.. 17:39. 2018
- MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet.. 14:97. 2015
- Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats.. 5:2. 2006
- Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats.. 5. 2006